On the basis of the promising results obtained in breast cancer patients [49] and the results of preclinical studies in ovarian cancer models [45, 46], the first phase II study evaluating the efficacy of trastuzumab in patients with recurrent ovarian cancers overexpressing HER2 was carried out in 2003 [50]. Here, ERBB2 is linked to breast cancer.